These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9432488)

  • 41. [Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].
    Butorov IV; Osoianu IuP; Butorov SI; Maksimov VV
    Klin Med (Mosk); 2005; 83(12):50-3. PubMed ID: 16502725
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease.
    Jung SW; Lee SW; Hyun JJ; Kim DI; Koo JS; Yim HJ; Park JJ; Lee HS; Chun HJ; Um SH; Choi JH; Kim CD; Ryu HS
    Dig Liver Dis; 2009 Feb; 41(2):134-40. PubMed ID: 18436489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer].
    Boixeda de Miquel D
    Rev Esp Enferm Dig; 1997 Dec; 89(12):875-7. PubMed ID: 9494374
    [No Abstract]   [Full Text] [Related]  

  • 44. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease.
    Wu CY; Kuo KN; Wu MS; Chen YJ; Wang CB; Lin JT
    Gastroenterology; 2009 Nov; 137(5):1641-8.e1-2. PubMed ID: 19664631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance.
    Veldhuyzen van Zanten S; Hunt RH; Cockeram A; Schep G; Malatjalian D; Sidorov J; Matisko A; Jewell D
    Am J Gastroenterol; 1998 Jan; 93(1):5-10. PubMed ID: 9448164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
    Wheeldon TU; Granström M; Hoang TT; Phuncarg DC; Nilsson LE; Sörberg M
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1315-21. PubMed ID: 15191514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Helicobacter pylori eradication: role of individual therapy constituents and therapy duration.
    Qasim A; O'Morain CA; O'Connor HJ
    Fundam Clin Pharmacol; 2009 Feb; 23(1):43-52. PubMed ID: 19207543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Choice of therapy (Helicobacter infection)].
    Danielsson A; Jaup B; Unge P
    Lakartidningen; 1994 May; 91(19):1928-30. PubMed ID: 8189940
    [No Abstract]   [Full Text] [Related]  

  • 49. Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori.
    Yazbek PB; Trindade AB; Chin CM; Dos Santos JL
    Dig Dis Sci; 2015 Oct; 60(10):2901-12. PubMed ID: 25999247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Modified triple therapy: what degree of acid inhibition is necessary?].
    Müller P; Simon B
    Leber Magen Darm; 1996 May; 26(3):171-3. PubMed ID: 8709832
    [No Abstract]   [Full Text] [Related]  

  • 51. [Diagnosis and therapy of Helicobacter pylori infection. Guidelines of the German Society of Digestive and Metabolic Diseases].
    Caspary WF; Arnold R; Bayerdörffer E; Behrens R; Birkner B; Braden B; Domschke W; Labenz J; Koletzko S; Malfertheiner P; Menge H; Rösch W; Schepp W; Strauch M; Stolte M
    Z Gastroenterol; 1996 Jun; 34(6):392-401. PubMed ID: 8767830
    [No Abstract]   [Full Text] [Related]  

  • 52. [Helicobacter pylori infection and peptic ulcer].
    Kühneck W
    Dtsch Med Wochenschr; 1993 Dec; 118(48):1783-4. PubMed ID: 8253035
    [No Abstract]   [Full Text] [Related]  

  • 53. [Follow-up of the therapeutic effect and strategy in non-elimination].
    Nilsson A; Sjölund K; Olbe L
    Lakartidningen; 1994 May; 91(19):1930. PubMed ID: 8189941
    [No Abstract]   [Full Text] [Related]  

  • 54. H. pylori eradication therapy.
    McLaughlin RP
    Ala Med; 1996; 65(8-10):20-2. PubMed ID: 8871512
    [No Abstract]   [Full Text] [Related]  

  • 55. [Anti-Helicobacter therapy for each and everyone?].
    Jaup B; Carling L
    Lakartidningen; 1994 Nov; 91(46):4243-4. PubMed ID: 7808120
    [No Abstract]   [Full Text] [Related]  

  • 56. Commentary: overcoming antibiotic resistance with Helicobacter pylori therapy--optimisation is the way forward.
    Molina-Infante J; Gisbert JP
    Aliment Pharmacol Ther; 2013 Jul; 38(2):204-5. PubMed ID: 23772902
    [No Abstract]   [Full Text] [Related]  

  • 57. [Helicobacter pylori and etiology of peptic ulcers].
    Fukuda Y; Yamashita T
    Nihon Naika Gakkai Zasshi; 1995 Jun; 84(6):858-63. PubMed ID: 7658114
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment resistance: what can be done?].
    Koop H
    Bildgebung; 1995 Apr; 62 Suppl 1():72-3. PubMed ID: 7670312
    [No Abstract]   [Full Text] [Related]  

  • 59. Commentary: overcoming antibiotic resistance with Helicobacter pylori therapy--optimisation is the way forward; authors' reply.
    Sierra F; Forero JD; Rey M; Botero ML; Cárdenas A
    Aliment Pharmacol Ther; 2013 Jul; 38(2):205-6. PubMed ID: 23772903
    [No Abstract]   [Full Text] [Related]  

  • 60. Current diagnosis and treatment of Helicobacter pylori.
    Youssef A; Chen YK
    West J Med; 1994 Mar; 160(3):254-5. PubMed ID: 8191764
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.